- ByInvesting.com-
Investing.com -- Olema Pharmaceuticals (NASDAQ:OLMA) shares fell 41% Monday following disappointing results from a late-stage...
Last | High | Low | |||||
|---|---|---|---|---|---|---|---|
| 138.50 | 139.65 | 136.90 | -4.20 | -2.94% | 459.29K | ||
| 63.60 | 64.06 | 62.92 | -2.82 | -4.25% | 1.15M | ||
| 63.08 | 63.26 | 60.10 | -1.92 | -2.95% | 902.89K | ||
| 70.00 | 70.06 | 68.76 | -0.12 | -0.17% | 204.12K | ||
| 529.60 | 529.80 | 521.00 | -0.20 | -0.04% | 138.55K | ||
| 825.40 | 826.00 | 805.40 | +0.60 | +0.07% | 27.64K | ||
| 123.16 | 123.30 | 121.32 | -0.10 | -0.08% | 1.15M | ||
| 79.75 | 79.85 | 78.72 | -0.49 | -0.61% | 1.18M | ||
| 128.40 | 128.50 | 125.60 | +1.30 | +1.02% | 374.39K | ||
| 326.40 | 327.30 | 315.60 | -14.80 | -4.34% | 911.2K | ||
| 491.00 | 500.20 | 485.80 | -13.20 | -2.62% | 59.96K | ||
| 715.50 | 717.50 | 706.50 | -2.50 | -0.35% | 25.56K | ||
| 567.60 | 569.20 | 559.60 | -5.40 | -0.94% | 31.66K | ||
| 138.80 | 139.05 | 135.75 | -2.95 | -2.08% | 389.48K | ||
| 805.00 | 808.40 | 789.40 | -14.80 | -1.81% | 52.16K | ||
| 170.90 | 171.30 | 168.40 | -2.00 | -1.16% | 49.69K | ||
| 29.32 | 29.49 | 28.97 | -0.52 | -1.74% | 2.69M | ||
| 2,885.00 | 2,888.00 | 2,828.00 | +5.00 | +0.17% | 9.98K | ||
| 61.96 | 62.12 | 61.16 | -0.84 | -1.34% | 200.42K | ||
| 44.29 | 44.51 | 42.10 | -1.00 | -2.21% | 550.74K |
Investing.com -- Olema Pharmaceuticals (NASDAQ:OLMA) shares fell 41% Monday following disappointing results from a late-stage...
Investing.com -- Anthropic’s annualised recurring revenue hit $19 billion in early March, up 110% from $9 billion at...
Investing.com -- Roche Holding AG shares fell more than 5% on Monday after its experimental breast cancer pill giredestrant failed...
Key highlights:Asian stocks fell, and Nasdaq/S&P 500 futures dropped 1% as renewed trade-war fears hit risk sentiment. The...
Want to hear something really scary? The ongoing government shutdown, now in its second month, is projected to cost the U.S....
Over the past week, there has been a clear divergence between safe-haven assets, namely gold and Bitcoin. While gold surged 7.4%,...
No Earning Reports have been scheduled